Diabetic ketoacidosis is characterized by hyperglycemia, anion-gap acidosis, and 
increased plasma ketones. After the resolution of hyperglycemia, persistent 
diuresis is rare. We herein report the case of a 27-year-old Asian woman with 
type 2 diabetes who was treated with a sodium-glucose cotransporter 2 (SGLT2) 
inhibitor (canagliflozin) who developed euglycemic diabetic ketoacidosis and 
persistent diuresis in the absence of hyperglycemia. Physicians should consider 
euglycemic diabetic ketoacidosis in the differential diagnosis of patients 
treated with SGLT2 inhibitors.